Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06049927
Other study ID # PRO-QINF-3005
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 16, 2023
Est. completion date May 31, 2024

Study information

Verified date May 2024
Source Sinovac Biotech Co., Ltd
Contact Lei Wang
Phone 18986142864
Email 372491281@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase III clinical trial of the study of quadrivalent influenza vaccine developed by Sinovac Biotech will be conducted in Chinese children aged 6 to 35 months. The trial is an randomized, double-blind and active controlled study. The objective of this study is to evaluate the Immunogenicity and safety of the vaccine.


Description:

A phase III clinical trial of the study of quadrivalent influenza vaccine developed by Sinovac Biotech will be conducted in Chinese children aged 6 to 35 months. The trial is an randomized, double-blind and active controlled study. The objective of this study is to evaluate the safety and immunogenicity of quadrivalent influenza vaccine(0.25ml and 0.5ml) manufactured by Sinovac Biotech Co., Ltd in healthy infants aged from 6 to 35 months. A total of 3300 subjects will be enrolled. The subjects will be randomly assigned to 4 groups in a 2:2:1:1 ratio and subjects will receive two doses of quadrivalent influenza vaccine(0.25ml or 0.5ml) or trivalent influenza vaccine(BV or BY), respectively, according to the immunization schedule of day 0,28 in each group.


Recruitment information / eligibility

Status Recruiting
Enrollment 3300
Est. completion date May 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 35 Months
Eligibility Inclusion Criteria: - Healthy infants aged 6-35 months; - Proven vaccination certificate and birth certificate; - The subjects' guardians can understand and voluntarily sign the informed consent form. Exclusion Criteria: - Received any circulating seasonal influenza vaccine prior to enrollment or had an influenza vaccine schedule during the study; - Suffering from seasonal influenza in the past 6 moths; - Axillary temperature >37.0°C; - History of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, angioedema and asthma; - Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; - Severe chronic diseases(Such as down syndrome, diabetes, sickle cell anaemia or neurological disorders); - Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness; - Autoimmune disease (such as systemic lupus erythematosus) or immunodeficiency / immunosuppression (such as HIV, after organ transplantation) - Thyroid disease or history of thyroidectomy, asplenia,functional asplenia, asplenia or splenectomy resulting from any condition; - Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation; - Continuous use of corticosteroids or other immunosuppressive agents for = 14 days within the past 6 months (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) and cytotoxic therapy in the past 6 months; - Acute diseases or acute exacerbation of chronic diseases in the past 3 days; - Receipt of blood products within in the past 3 months; - Receipt of other investigational drugs in the past 30 days; - Receipt of attenuated live vaccines in the past 14 days; - Receipt of inactivated or subunit vaccines in the past 7 days; - Participated in other clinical trials before enrollment and in the follow-up period, or plans to participate in other clinical trials during the clinical trial; - According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Quadrivalent influenza vaccine(0.25ml)
7.5 ug hemagglutinin (HA) of each of the four influenza strains in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
Quadrivalent influenza vaccine(0.5ml)
15 ug hemagglutinin (HA) of each of the four influenza strains in 0.5 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per njection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses on day 0, 28.
Trivalent influenza vaccine(BV)
7.5µg inactivated influenza antigen (H1N1, H3N2, Victoria) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region. And the immunization schedule is two doses on day 0, 28.
Trivalent influenza vaccine(BY)
7.5µg inactivated influenza antigen (H1N1, H3N2, and Yamagata) of each of the trivalent influenza vaccine in 0.25 mL of sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate per injection.The routine of administration is Intramuscular injection into deltoid region.And the immunization schedule is two doses vaccine on day 0, 28.

Locations

Country Name City State
China Huoqiu County Center for Disease Control and Prevention Lu'an Anhui
China Zhushan County Center for Diseases Control and Prevention Shiyan Hubei
China Laohekou Center for Disease Control and Prevention Xiangyang Hubei
China Nanzhang County Center for Disease Prevention and Control Xiangyang Hubei
China Digui County Center for Disease Control and Prevention Yichang Hubei

Sponsors (1)

Lead Sponsor Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rates of HI antibody Anti-influenza antibodies were measured using HAI assay for 4 strains: H1N1, H3N2, B Victoria and B Yamagata. Seroconversion was defined as pre-vaccination titer <1:10 and post-vaccination titer =1:40, and Significant increase was defined as pre-vaccination titer=1:40 and = 4-fold increase of post-vaccination titer. 28 days after full schedule immunization
Primary Geometric Mean Titers (GMTs) of HI antibody Anti-influenza antibody levels were measured using hemagglutination inhibition (HAI) assay for 4 strains: H1N1, H3N2, B Victoria, B Yamagata. 28 days after full schedule immunization
Primary Number of Participants With Seroprotection to Influenza Vaccine Antigens Anti-influenza antibodies were measured using HAI assay for 4 strains: H1N1, H3N2, B Victoria and B Yamagata. Seroprotection was defined as an antibody titer =1:40 at pre-vaccination and at post-final vaccination. 28 days after full schedule immunization
Secondary GMIs of HI antibody Anti-influenza antibody were measured using hemagglutination inhibition (HAI) assay for 4 strains: H1N1, H3N2, B Victoria, B Yamagata. GMI is the increase fold of GMT post vaccination compared with pre vaccination 28 days after full schedule immunization
Secondary Incidence of adverse reactions Incidence of adverse reaction 0-30 days after each dose 0-30 days after each dose
Secondary Incidence of adverse reactions Incidence of adverse reaction 0-7 days after each dose 0-7 days after each dose
Secondary Incidence of Serious adverse events Incidence of serious adverse events from beginning of vaccination until 6 months after the last dose Since the beginning of vaccination until 6 months after the last dose
Secondary Incidence of AESI Incidence of AESI since the beginning of vaccination until 6 months after the last dose since the beginning of vaccination until 6 months after the last dose
See also
  Status Clinical Trial Phase
Completed NCT01180621 - Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children Phase 2
Completed NCT01209780 - Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Phase 3
Completed NCT01206686 - The Effect of Time-Slot Scheduling on Flu Vaccination Rates N/A
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT05566639 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Phase 3
Completed NCT01072799 - Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine Phase 2
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT01207232 - The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates N/A
Completed NCT04997239 - A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old Phase 4
Completed NCT05512494 - Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated Phase 4
Completed NCT01011582 - Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza N/A
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT04896086 - First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults Phase 1
Completed NCT01344057 - Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Phase 2
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT00903552 - Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) Phase 2
Completed NCT05827068 - A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Phase 1/Phase 2
Completed NCT05415462 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Phase 3